To include your compound in the COVID-19 Resource Center, submit it here.

Divergent aftermarket results for Phathom, Cabaletta IPOs

With evidence still suggesting that confidence in biotech IPOs has begun to waver in recent weeks, two new listings traded in opposite directions Friday after pricing offerings ahead of the session. Phathom posted a double-digit gain after upsizing its offering, while Cabaletta raised

Read the full 430 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers